Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended | |
Mar. 31, 2015 | 12-May-15 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | FALSE | |
Document Period End Date | 31-Mar-15 | |
Document Fiscal Year Focus | 2015 | |
Document Fiscal Period Focus | Q3 | |
Entity Registrant Name | Electromed, Inc. | |
Entity Central Index Key | 1488917 | |
Current Fiscal Year End Date | -24 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 8,133,857 |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (USD $) | Mar. 31, 2015 | Jun. 30, 2014 |
Current Assets | ||
Cash | $2,904,811 | $1,502,702 |
Accounts receivable (net of allowances for doubtful accounts of $45,000) | 6,388,454 | 6,487,267 |
Inventories | 2,401,864 | 2,235,496 |
Prepaid expenses and other current assets | 481,477 | 397,853 |
Total current assets | 12,176,606 | 10,623,318 |
Property and equipment, net | 3,617,372 | 3,935,802 |
Finite-life intangible assets, net | 832,520 | 930,451 |
Other assets | 361,076 | 302,595 |
Total assets | 16,987,574 | 15,792,166 |
Current Liabilities | ||
Current maturities of long-term debt | 48,098 | 46,375 |
Accounts payable | 684,290 | 380,582 |
Accrued compensation | 561,938 | 391,040 |
Warranty reserve | 670,000 | 700,000 |
Other accrued liabilities | 171,893 | 302,482 |
Total current liabilities | 2,136,219 | 1,820,479 |
Long-term debt, less current maturities | 1,214,795 | 1,251,192 |
Total liabilities | 3,351,014 | 3,071,671 |
Commitments and Contingencies (Note 6) | ||
Equity | ||
Common stock, $0.01 par value; authorized: 13,000,000; shares issued and outstanding: 8,133,857 and 8,114,252 at March 31, 2015, June 30, 2014, respectively | 81,339 | 81,143 |
Additional paid-in capital | 13,295,566 | 13,217,166 |
Retained earnings (accumulated deficit) | 259,655 | -577,814 |
Total equity | 13,636,560 | 12,720,495 |
Total liabilities and equity | $16,987,574 | $15,792,166 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Parenthetical) (USD $) | Mar. 31, 2015 | Jun. 30, 2014 |
Condensed Consolidated Balance Sheets [Abstract] | ||
Accounts receivable, allowance for doubtful accounts | $45,000 | $45,000 |
Common stock, par value | $0.01 | $0.01 |
Common stock, shares authorized | 13,000,000 | 13,000,000 |
Common stock, shares issued | 8,133,857 | 8,114,252 |
Common stock, shares outstanding | 8,133,857 | 8,114,252 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements Of Operations (USD $) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2015 | Mar. 31, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Condensed Consolidated Statements Of Operations [Abstract] | ||||
Net revenues | $4,556,977 | $3,956,335 | $14,209,239 | $10,875,588 |
Cost of revenues | 1,400,252 | 1,436,195 | 4,354,339 | 3,476,570 |
Gross profit | 3,156,725 | 2,520,140 | 9,854,900 | 7,399,018 |
Operating expenses | ||||
Selling, general and administrative | 3,020,849 | 2,634,036 | 8,714,746 | 8,097,067 |
Research and development | 78,292 | 103,166 | 237,201 | 405,009 |
Total operating expenses | 3,099,141 | 2,737,202 | 8,951,947 | 8,502,076 |
Operating income (loss) | 57,584 | -217,062 | 902,953 | -1,103,058 |
Interest expense, net of interest income of $371, $392 $2,044 and $11,730 respectively | 20,355 | 23,321 | 65,484 | 57,992 |
Net income (loss) before income taxes | 37,229 | -240,383 | 837,469 | -1,161,050 |
Income tax expense | -764,000 | 0 | -418,000 | |
Net Income (loss) | $37,229 | ($1,004,383) | $837,469 | ($1,579,050) |
Income (loss) per share: | ||||
Basic | $0 | ($0.12) | $0.10 | ($0.19) |
Diluted | $0 | ($0.12) | $0.10 | ($0.19) |
Weighted-average common shares outstanding: | ||||
Basic | 8,114,252 | 8,114,252 | 8,114,252 | 8,114,252 |
Diluted | 8,166,659 | 8,114,252 | 8,131,496 | 8,114,252 |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements Of Operations (Parenthetical) (USD $) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2015 | Mar. 31, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Condensed Consolidated Statements Of Operations [Abstract] | ||||
Interest income | $371 | $392 | $2,044 | $11,730 |
Condensed_Consolidated_Stateme2
Condensed Consolidated Statements Of Cash Flows (USD $) | 9 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2014 | |
Cash Flows From Operating Activities | ||
Net income (loss) | $837,469 | ($1,579,050) |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
Depreciation | 459,223 | 409,651 |
Amortization of finite-life intangible assets | 97,931 | 95,082 |
Amortization of debt issuance costs | 14,546 | 13,078 |
Share-based compensation expense | 78,596 | 73,821 |
Deferred income taxes | 454,000 | |
Loss on disposal of property and equipment | 233,116 | 34,110 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 98,813 | 2,544,116 |
Inventories | -166,368 | -1,171,221 |
Prepaid expenses and other assets | -141,854 | -37,930 |
Accounts payable and accrued liabilities | 319,717 | 184,333 |
Net cash provided by operating activities | 1,831,189 | 1,019,990 |
Cash Flows From Investing Activities | ||
Expenditures for property and equipment | -379,609 | -626,327 |
Expenditures for finite-life intangible assets | -8,155 | |
Net cash used in investing activities | -379,609 | -634,482 |
Cash Flows From Financing Activities | ||
Principal payments on long-term debt including capital lease obligations | -34,674 | -81,348 |
Payments of deferred financing fees | -14,797 | -35,296 |
Net cash used in financing activities | -49,471 | -116,644 |
Net increase in cash and cash equivalents | 1,402,109 | 268,864 |
Cash and cash equivalents | ||
Beginning of period | 1,502,702 | 503,564 |
End of period | $2,904,811 | $772,428 |
Interim_Financial_Reporting
Interim Financial Reporting | 9 Months Ended | |
Mar. 31, 2015 | ||
Interim Financial Reporting [Abstract] | ||
Interim Financial Reporting | Note 1. | Interim Financial Reporting |
Basis of presentation: Electromed, Inc. (the "Company") develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation ("HFCWO") therapy in pulmonary care for patients of all ages. The Company markets and sells its products in the United States to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also markets and sells its products internationally both directly and through distributors. International sales were approximately $599,000 and $585,000 for the nine months ended March 31, 2015 and 2014, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment. | ||
The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. generally accepted accounting principles for annual reports. This interim report should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended June 30, 2014. | ||
Principles of consolidation: The accompanying condensed consolidated financial statements include the accounts of Electromed, Inc. and its subsidiary, Electromed Financial, LLC. Operating activities and net assets in Electromed Financial, LLC were insignificant as of and for the three and six months ended December 31, 2014 and the year ended June 30, 2014. As of December 31, 2014, Electromed Financial, LLC was dissolved. | ||
A summary of the Company's significant accounting policies follows: | ||
Use of estimates: Management uses estimates and assumptions in preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its consolidated financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve. | ||
Net income (loss) per common share: Net income (loss) is presented on a per share basis for both basic and diluted common shares. Basic net income (loss) per common share is computed using the weighted average number of common shares outstanding during the period. The diluted net income (loss) per common share calculation assumes that all stock warrants were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents of 539,900 and 609,900 were excluded from the calculation of diluted earnings per share for the three and nine months ended March 31, 2015 and 2014, respectively, as their impact was antidilutive. | ||
Inventories
Inventories | 9 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Inventories [Abstract] | |||||||||
Inventories | Note 2. | Inventories | |||||||
The components of inventory were approximately as follows: | |||||||||
March 31, | June 30, | ||||||||
2015 | 2014 | ||||||||
Parts inventory | $ | 1,615,000 | 1,491,000 | ||||||
Work in process | 165,000 | 264,000 | |||||||
Finished goods | 652,000 | 510,000 | |||||||
Less: Reserve for obsolescence | (30,000 | ) | (30,000 | ) | |||||
Total | $ | 2,402,000 | 2,235,000 |
Warranty_Liability
Warranty Liability | 9 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Warranty Liability [Abstract] | |||||||||
Warranty Liability | Note 3. | Warranty Liability | |||||||
The Company provides a lifetime warranty on its products to the prescribed patient for sales within the United States and a three-year warranty for all institutional sales and sales to individuals outside the United States. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Company's warranty liability include the number of units shipped, historical and anticipated rates of warranty claims, and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amounts as necessary. | |||||||||
Changes in the Company's warranty liability were approximately as follows: | |||||||||
Nine Months | Year Ended | ||||||||
Ended | 30-Jun-14 | ||||||||
31-Mar-15 | |||||||||
Beginning warranty reserve | $ | 700,000 | $ | 680,000 | |||||
Accrual for products sold | 107,000 | 196,000 | |||||||
Expenditures and costs incurred for warranty claims | (137,000 | ) | (176,000 | ) | |||||
Ending warranty reserve | $ | 670,000 | $ | 700,000 |
Income_Taxes
Income Taxes | 9 Months Ended | ||
Mar. 31, 2015 | |||
Income Taxes [Abstract] | |||
Income Taxes | Note 4. | Income Taxes | |
On a quarterly basis, the Company estimates what its effective tax rate will be for the full fiscal year and records a quarterly income tax provision based on the anticipated rate. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The effective tax rates for the nine months ended March 31, 2015 and 2014 were 0.0% and negative 36.0%, respectively. For the nine months ended March 31, 2015, the Company recorded no tax expense. As income is earned the Company's net operating loss carryforward is applied to reduce taxable income to zero. Accordingly, the application of the net operating losses to reduce taxable income reduces the Company's gross deferred tax assets. This reduction of the Company's gross deferred tax assets causes a corresponding decrease in respective valuation allowance. For the nine months ended March 31, 2015, the Company recorded an income tax expense of zero and the decrease in the Company's deferred tax assets and corresponding reduction in its deferred tax asset valuation allowance was approximately $358,000. | |||
For the nine months ended March 31, 2014, the Company recorded an income tax expense of $418,000. This amount includes a current tax benefit of $36,000 and a discrete tax expense of $454,000 due primarily to the Company's recording of a full valuation allowance against all of its net US federal and state deferred tax assets at March 31, 2014. For the three months ended March 31, 2014, tax expense also included $346,000 of tax expense due to the reversal of the current tax benefit recorded during the first two quarters of the fiscal year. | |||
During fiscal 2014, the Company recorded a full valuation allowance against all of its net US federal and state deferred tax assets. The Company assessed whether a valuation allowance should be established against its deferred tax assets based on consideration of all available evidence, using a "more likely than not" standard. In assessing the need for a valuation allowance, the Company considered both positive and negative evidence related to the likelihood of realization of deferred tax assets. In making such assessments, more weight was given to evidence that could be objectively verified. Under this approach the recent cumulative losses is a significant piece of significant negative evidence. This factor impairs the Company's ability to rely on future taxable income projections in determining whether a valuation allowance is appropriate. Future sources of taxable income considered in determining the amount of recorded valuation allowance include: | |||
• | Taxable income in prior carryback years, if carryback is permitted under the tax law; | ||
• | Future reversals of existing taxable temporary differences, excluding those related to indefinite-lived intangible assets; | ||
• | Tax planning strategies; and | ||
• | Future taxable income exclusive of reversing temporary differences and carryforwards. | ||
On a quarterly basis, the Company evaluates all positive and negative evidence, as discussed above, in determining if the valuation allowance is fairly stated. Based the Company's review of this evidence, management believes that a full valuation allowance against all of the Company's deferred tax assets at March 31, 2015 remains appropriate. |
Financing_Arrangements
Financing Arrangements | 9 Months Ended | |
Mar. 31, 2015 | ||
Financing Arrangements [Abstract] | ||
Financing Arrangements And Subsequent Events | Note 5. | Financing Arrangements |
The Company has a credit facility that provides for a revolving line of credit and a term loan. On December 18, 2014, the Company renewed its $2,500,000 revolving line of credit. There was no outstanding principal balance on the line of credit as of March 31, 2015 or June 30, 2014. Interest on the line of credit accrues at the prime rate plus 1.00%, with a floor of 4.50% (4.50% at March 31, 2015) and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable ($2,500,000 eligible for borrowing at March 31, 2015) and the line of credit expires on December 18, 2015, if not renewed. The line of credit is secured by a security interest in substantially all of the tangible and intangible assets of the Company. | ||
As a part of the credit facility, the Company has a term loan, which had an outstanding principal balance of approximately $1,251,000 and $1,281,000 at March 31, 2015 and June 30, 2014, respectively. The term loan bears interest at 5.00%, with monthly payments of principal and interest of approximately $8,600 and a final payment of principal and interest of approximately $1,095,000 is due on the maturity date of December 18, 2018. The term loan is secured by a mortgage on the Company's real property. | ||
The Company's credit facility contains certain financial and nonfinancial covenants which include a minimum tangible net worth covenant of not less than $10,125,000 and restrictions on the Company's ability to incur certain additional indebtedness or pay dividends. |
Commitments_And_Contingencies
Commitments And Contingencies | 9 Months Ended | |
Mar. 31, 2015 | ||
Commitments And Contingencies [Abstract] | ||
Commitments And Contingencies | Note 6. | Commitments and Contingencies |
The Company is occasionally involved in claims and disputes arising in the ordinary course of business. The Company insures its business risks where possible to mitigate the financial impact of individual claims, and establishes reserves for an estimate of any probable cost of settlement or other disposition. |
Related_Parties
Related Parties | 9 Months Ended | |
Mar. 31, 2015 | ||
Related Parties [Abstract] | ||
Related Parties | Note 7. | Related Parties |
The Company uses a parts supplier whose founder and president is a director of the Company. For the nine months ended March 31, 2015 and 2014, the Company made payments to the supplier of approximately $85,000 and $163,000, respectively. |
Interim_Financial_Reporting_Po
Interim Financial Reporting (Policy) | 9 Months Ended |
Mar. 31, 2015 | |
Interim Financial Reporting [Abstract] | |
Nature Of Business | Electromed, Inc. (the "Company") develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation ("HFCWO") therapy in pulmonary care for patients of all ages. The Company markets and sells its products in the United States to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also markets and sells its products internationally both directly and through distributors. International sales were approximately $599,000 and $585,000 for the nine months ended March 31, 2015 and 2014, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment. |
Basis Of Presentation | The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. generally accepted accounting principles for annual reports. This interim report should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended June 30, 2014. |
Principles Of Consolidation | Principles of consolidation: The accompanying condensed consolidated financial statements include the accounts of Electromed, Inc. and its subsidiary, Electromed Financial, LLC. Operating activities and net assets in Electromed Financial, LLC were insignificant as of and for the three and six months ended December 31, 2014 and the year ended June 30, 2014. As of December 31, 2014, Electromed Financial, LLC was dissolved. |
Use Of Estimates | Use of estimates: Management uses estimates and assumptions in preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its consolidated financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve. |
Net Income (Loss) Per Common Share | Net income (loss) per common share: Net income (loss) is presented on a per share basis for both basic and diluted common shares. Basic net income (loss) per common share is computed using the weighted average number of common shares outstanding during the period. The diluted net income (loss) per common share calculation assumes that all stock warrants were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents of 539,900 and 609,900 were excluded from the calculation of diluted earnings per share for the three and nine months ended March 31, 2015 and 2014, respectively, as their impact was antidilutive. |
Inventories_Tables
Inventories (Tables) | 9 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Inventories [Abstract] | |||||||||
Schedule Of Components Of Inventory | |||||||||
March 31, | June 30, | ||||||||
2015 | 2014 | ||||||||
Parts inventory | $ | 1,615,000 | 1,491,000 | ||||||
Work in process | 165,000 | 264,000 | |||||||
Finished goods | 652,000 | 510,000 | |||||||
Less: Reserve for obsolescence | (30,000 | ) | (30,000 | ) | |||||
Total | $ | 2,402,000 | 2,235,000 |
Warranty_Liability_Tables
Warranty Liability (Tables) | 9 Months Ended | ||||||||
Mar. 31, 2015 | |||||||||
Warranty Liability [Abstract] | |||||||||
Schedule Of Warranty Liability | |||||||||
Nine Months | Year Ended | ||||||||
Ended | 30-Jun-14 | ||||||||
31-Mar-15 | |||||||||
Beginning warranty reserve | $ | 700,000 | $ | 680,000 | |||||
Accrual for products sold | 107,000 | 196,000 | |||||||
Expenditures and costs incurred for warranty claims | (137,000 | ) | (176,000 | ) | |||||
Ending warranty reserve | $ | 670,000 | $ | 700,000 |
Interim_Financial_Reporting_De
Interim Financial Reporting (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2015 | Mar. 31, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Interim Financial Reporting [Line Items] | ||||
Sales | $4,556,977 | $3,956,335 | $14,209,239 | $10,875,588 |
Common stock equivalents excluded from calculation of diluted earnings per share | 539,900 | 609,900 | 539,900 | 609,900 |
International [Member] | ||||
Interim Financial Reporting [Line Items] | ||||
Sales | $599,000 | $585,000 |
Inventories_Details
Inventories (Details) (USD $) | Mar. 31, 2015 | Jun. 30, 2014 |
Inventories [Abstract] | ||
Parts inventory | $1,615,000 | $1,491,000 |
Work in process | 165,000 | 264,000 |
Finished goods | 652,000 | 510,000 |
Less: Reserve for obsolescence | -30,000 | -30,000 |
Total | $2,401,864 | $2,235,496 |
Warranty_Liability_Narrative_D
Warranty Liability (Narrative) (Details) (Outside United States [Member]) | 9 Months Ended |
Mar. 31, 2015 | |
Outside United States [Member] | |
Warranty Liability [Line Items] | |
Warranty term | 3 years |
Warranty_Liability_Schedule_Of
Warranty Liability (Schedule Of Warranty Liability) (Details) (USD $) | 9 Months Ended | 12 Months Ended |
Mar. 31, 2015 | Jun. 30, 2014 | |
Warranty Liability [Abstract] | ||
Beginning warranty reserve | $700,000 | $680,000 |
Accrual for products sold | 107,000 | 196,000 |
Expenditures and costs incurred for warranty claims | -137,000 | -176,000 |
Ending warranty reserve | $670,000 | $700,000 |
Income_Taxes_Details
Income Taxes (Details) (USD $) | 3 Months Ended | 9 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Income Taxes [Abstract] | |||
Effective tax rate | 0.00% | -36.00% | |
Income tax expense (benefit) | $764,000 | $0 | $418,000 |
Reduction in deferred tax asset valuation allowance | 358,000 | ||
Current tax expense (benefit) | -36,000 | ||
Discrete tax expense | 454,000 | ||
Tax expense due to reversal of current tax benefit recorded during first two quarters of the fiscal year | $346,000 |
Financing_Arrangements_Details
Financing Arrangements (Details) (Venture Bank [Member], USD $) | 9 Months Ended | |
Mar. 31, 2015 | Jun. 30, 2014 | |
Venture Bank [Member] | ||
Line of Credit Facility [Line Items] | ||
Maximum borrowing capacity | $2,500,000 | |
Outstanding principal balance | 0 | 0 |
Amount added to prime rate for interest rate | 1.00% | |
Interest rate, floor | 4.50% | |
Effective interest rate including prime rate | 4.50% | |
Borrowing restriction, revolving line of credit | 2,500,000 | |
Borrowing restriction, percent of eligible accounts receivable | 57.00% | |
Amount eligible for borrowing, revolving line of credit | 2,500,000 | |
Credit facility expiration date | 18-Dec-15 | |
Term loan | 1,251,000 | 1,281,000 |
Term loan, interest rate | 5.00% | |
Monthly payments of principal and interest | 8,600 | |
Final payment of principal and interest | 1,095,000 | |
Term loan maturity date | 18-Dec-18 | |
Minimum tangible net worth to be maintained | $10,125,000 |
Related_Parties_Details
Related Parties (Details) (USD $) | 9 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2014 | |
Related Party Transaction [Line Items] | ||
Payments to related party parts supplier | $85,000 | $163,000 |
Member Of Electromed's Board Of Directors [Member] | ||
Related Party Transaction [Line Items] | ||
Number of related parties | 1 |